Literatur
-
1
Fang G, Fine M, Orloff J. et al .
New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 356 cases.
Medicine.
1990;
69
307-316
-
2
Mandall L A.
Comunity-acquired pneumonia: etiology, epidemiology, and treatment.
Chest .
1995;
(suppl) 108
35-42
-
3
Lode H, Steinhoff D, Schaberg T. et al .
New pneumonia pathogens, especially Chlamydia pneumoniae and Hantaviruses.
Internist (Berl).
1996;
37
882-889
-
4
Steinhoff D, Lode H, Ruckdeschel G. et al .
Chlamydia pneumoniae as a cause of community-acquired pneumonia is hospitalised patients in Berlin.
Clin Infect Dis.
1996;
22
958-964
-
5
Allewelt M, Steinhoff D, Rahlwes M. et al .
Wandel im Erregerspektrum ambulant erworbener Pneumonien (1982 - 1992).
Dtsch Med Wschr.
1997;
122
1027-1032
-
6
Plouffe J F.
Importance of atypical pathogens of community-acquired pneumonia.
Clin Infect Dis.
2000;
(suppl) 31
35-39
-
7
Cosentini R, Tarsia P, Blasi F. et al .
Community-acquired pneumonia: role of atypical organisms.
Monalde Arch Chest Dis.
2001;
56
527-534
-
8
Gupta S K, Sarosi G A.
The role of atypical pathogens in community-acquired pneumonia.
Med Clin North Am.
2001;
85
1349-1365
-
9
Marrie T J.
Community-acquired pneumonia.
Clin Infect Dis.
1994;
18
501-515
-
10
Bartlett J G, Mundy L M.
Community-acquired pneumonia.
New Engl J Med.
1995;
333
1618-1624
-
11
Kauppinen M T, Saikku P, Kujala P. et al .
Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia.
Thorax.
1996;
51
185-189
-
12
Lieberman D, Schlaeffer F, Boldur I. et al .
Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients.
Thorax.
1996;
51
179-184
-
13
Lieberman D, Ben-Yaakov M, Lazarovich Z. et al .
Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients.
Infection.
1996;
24
109-114
-
14
Dowell S F, Peeling R W, Boman J. et al .
Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).
Clin Infec Dis.
2001;
33
492-503
-
15
Kuo C C, Jackson L A, Campbell L A. et al .
Chlamydia pneumoniae (TWAR).
Clin Microbiol Rev.
1995;
8
451-461
-
16 Schachter J, Stamm W E. Chlamydia. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. Washington, D.C.: 7th ed. Press 1999: 669-677
-
17 Stephens R S. Chlamydia: intracellular biology, pathogenesis, and immunity. Washington, D.C.: American Society for Microbiology 1999
-
18
Everett K DE, Bush R M, Andersen A A.
Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. Nov. and Simkaniaceae fam. Nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identifications of organisms.
Int J Syst Bactiriol.
1999;
49
415-440
-
19
Amann R, Springer N, Schönhuber W. et al .
Obligate intracellular bacterial parasites of acanthamoebae related to Chlamydia spp.
Appl Environ Microbiol.
1997;
63
115-121
-
20
Fritsche T R, Horn M, Wagner M. et al .
Phylogenetic diversity among geographically dispersed Chlamydiales endosymbionts recovered from clinical and environmental isolates of Acanthamoeba spp.
Appl Environ Microbiol.
2000;
66
2613-2619
-
21
Horn M, Wagner M, Müller K D. et al .
Neochlamydia hartmannellae gen. nov., sp. nov. (Parachlamydiaceae), an endoparasite of the amoeba Hartmanellae vermiformis.
Microbiology.
2000;
146
1231-1239
-
22
Kahane S, Everett K D, Kimmel N. et al .
Simkania negevensis strain ZT: growth, antigenic and genome characteristics.
Int J Syst Bacteriol.
1999;
49
815-820
-
23
Grayston J T, Diwan V K, Cooney M. et al .
Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically.
Arch Intern Med.
1989;
149
169-173
-
24
Grayston J T, Campbell L A, Kuo C C. et al .
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.
J Infect Dis.
1990;
161
618-625
-
25
Chirgwin K, Roblin P M, Gelling M. et al .
Infection with Chlamydia pneumoniae in Brooklyn.
J Infect Dis.
1991;
163
757-761
-
26
Kauppinen M, Saikku P.
Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment.
Clin Inf Dis.
1995;
(suppl) 3
244-252
-
27
Suttithawil W, Wangroongsarb P, Naigowit P. et al .
Chlamydia (Chlamydia) pneumoniae as a cause of community-acquired pneumonia in Thailand.
J Med Assoc Thai.
2001;
84
430-437
-
28
Kese D, Cizman M, Marin J. et al .
Chlamydia pneumoniae infections in patients with community-acquired pneumonia in Slovenia.
Scand J Inf Dis.
2002;
34
172-176
-
29
Miyashita N, Fukano H, Okimoto N. et al .
Clinical presentation of community-acquired pneumonia in adults.
Chest.
2002;
121
1776-1781
-
30
Hammerschlag M R.
Chlamydia pneumoniae and the lung.
Eur Respir J.
2000;
16
1001-1007
-
31
Beaty C D, Grayston J C, Wang S P. et al .
Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease.
Am Rev Respir Dis.
1991;
144
1408-1410
-
32
Karnak D, Beder S.
Treatment of Chlamydia pneumoniae infection and chronic obstructive pulmonary disease.
Expert Opin Pharmacother.
2002;
3
1461-1470
-
33
Kraft M.
The role of bacterial infections in asthma.
Clin Chest Med.
2000;
21
301-313
-
34
Hertzen L von.
Role of persitent infection in the control and severity of asthma: focus on Chlamydia pneumoniae.
Eur Respir J.
2001;
19
546-556
-
35
Wong Y K, Gallagher P J, Ward M E.
Chlamydia pneumoniae and atherosclerosis.
Heart.
1999;
81
232-238
-
36
Campball L A, Kuo C C.
Chlamydia pneumoniae pathogenesis.
J Med Microbiol.
2002;
51
623-625
-
37
Kalayoglu M V, Libby P, Byrne G I.
Chlamydia pneumoniae as an emerging risk factor in cardiovascular diseases.
JAMA.
2002;
288
2724-2731
-
38
Ngeh J, Anand V, Gupta S.
Chlamydia pneumoniae and atherosklerosis - what we know and what we don't.
Clin Microbiol Infect.
2002;
8
2-13
-
39
Balin B J, Appelt D M.
Role of infection in Alzheimer' disease.
J Am Osteopath Assoc.
2001;
(suppl) 12
1-6
-
40
Yucesan C, Sriram S.
Chlamydia pneumoniae infection of the central nervous system.
Curr Opin Neurol.
2001;
14
355-359
-
41
Saikku P, Wang S P, Kleemola M. et al .
An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci.
J Infect Dis.
1985;
151
832-839
-
42
Storey C, Lusher M, Yates P. et al .
Evidence for Chlamydia pneumoniae of non-human origin.
J Gen Bacteriol.
1993;
139
2621-2626
-
43
Forsey T, Darougar S, Treharne J D.
Prevalence in human beings of antibodies to Chlamydia IOL-207, an atypical strain of chlamydia.
J Infect.
1986;
12
145-152
-
44
Kanamoto Y, Ouchi K, Mizui M. et al .
Prevalence of antibody to Chlamydia pneumoniae TWAR in Japan.
J Clin Microbiol.
1991;
29
816-818
-
45
Marton A, Karolyi A, Szalka A.
Prevalence of Chlamydia pneumoniae antibodies in Hungary.
Eur J Clin Microbiol Infect Dis.
1992;
11
139-142
-
46
Montes M, Cilla G.
High prevalence of Chlamydia pneumoniae infection in children and young adults in Spain.
Pediatr Infect Dis J.
1992;
11
972-973
-
47
Grayston J T.
Infections caused by Chlamydia pneumoniae strain TWAR.
Clin Inf Dis.
1992;
15
757-763
-
48
Grayston J T, Diwan V K, Cooney M. et al .
Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically.
Arch Intern Med.
1989;
149
169-173
-
49 Cosentini R, Blasi F, Rossi S. et al .Chlamydia pneumoniae and severe community-acquired pneumonia. In: Orfila J, Byrne GI, Cherneskey MA, Grayston JT, et al. eds. Chlamydial infections - 1994. Bologna, Italy: Societa Editrice Esculapio 1994: 453-456
-
50
Gaydos C A, Eiden J J, Oldach D. et al .
Diagnosis of Chlamydia pneumoniae in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay.
Clin Infect Dis.
1994;
19
157-160
-
51 Kauppinen M, Kujala P, Leinonen M. et al .Clinical features of community-acquired Chlamydia pneumoniae pneumonia. In: Orfila J, Byrne GI, Cherneskey MA, et al. eds. Chlamydial infections - 1994. Bologna, Italy: Societa Editrice Esculapio 1994: 457-460
-
52
Wainwright A P, Beaumont A C, Kox W J.
Psittacosis: diagnosis and management of severe pneumonia and multi organ failure.
Intensive Care Med.
1987;
13
419-421
-
53
Gregory D W, Schaffner W.
Psittacosis.
Semin Respir Infect.
1997;
12
7-11
-
54
Elliott J H.
Psittacosis. A flu like syndrome.
Aust Fam Physician.
2001;
30
739-741
-
55
Cles L D, Stamm W E.
Use of HL cells for improved isolation and passage of Chlamydia pneumoniae.
J Clin Microbiol.
1990;
28
938-940
-
56
Kuo C C, Grayston J T.
A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumoniae strain TWAR.
J Inf Dis.
1990;
162
755-758
-
57
Wong K H, Skelton S K, Chan Y K.
Efficient culture of chlamydia pneumoniae with cell lines derived from the human respiratory tract.
J Clin Microbiol.
1992;
30
1625-1630
-
58
Grayston J T, Kuo C C, Wang S P. et al .
A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infection.
N Engl J Med.
1986;
315
161-168
-
59
Kuo C C, Chen H H, Wang S P. et al .
Identification of a new group of Chlamydia psittaci strains called TWAR.
J Clin Microbiol.
1986;
24
1034-1037
-
60
Person K, Haidl S.
Evaluation of a commercial test for antibodies to the chlamydial lipopolysaccharide (Medac) for serodiagnosis of acute infections by Chlamydia pneumoniae (TWAR) and Chlamydia psittaci.
APMIS.
2000;
108
131-138
-
61
Johnsen S, Andersen P L, Stanek G. et al .
Chlamydia antibody response in healthy volunteers immunized with nonchlamydial antigens: a randomized, double-blind, placebo-controlled study.
Clin Inf Dis.
2003;
36
586-591
-
62
Nurminen M, Leinonen M, Saikku P. et al .
The genus-specific antigen of Chlamydia: resemblance to the lipopolysaccharide of enteric bacteria.
Science.
1983;
220
1279-1281
-
63 Peeling R. Chlamydia pneumoniae infections: applications of laboratory methods. In: Allegra L, Blasi F, eds. Chlamydia pneumoniae: the lung and the heart. Milano: Springer-Verlag Italia 1999: 33-42
-
64 Wang S. Serology for Chlamydia pneumoniae (TWAR). In: Allegra L, Blasi F, eds. Chlamydia pneumoniae: the lung and the heart. Milano: Springer-Verlag Italia 1999: 16-23
-
65
Wang S P, Grayston J T.
Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test.
Am J Ophthal.
1970;
70
367-374
-
66 Schachter J. Chlamydiae. In: Rose NR, DeMarcario EC, Fahey JL, Friedman H, Pen GM, eds. Manual of clinical laboratory immunology. Washington, D.C.: 4th ed. American Society for Microbiology 1992: 661-666
-
67
Ekman M R, Leinonen M, Syrjala H. et al .
Evaluation of serological methods in the diagnosis of Chlamydia pneumoniae pneumonia during an epidemic in Finland.
Eur J Clin Microbiol Infect Dis.
1993;
12
756-760
-
68
Verkooyen R P, Lent N A van, Mousavi Joulandan S A. et al .
Diagnosis of Chlamydia pneumoniae in fection in patients with chronic obstructive pulmonary diseases by microimmunofluorescence and ELISA.
J Med Microbiol.
1997;
46
959-964
-
69
Verkooyen R P, Willemse D, Hiep-van Casteren S CAM. et al .
Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections.
J Clin Microbiol.
1998;
36
2301-2307
-
70
Peeling R W, Wang S P, Grayston J T. et al .
Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results.
J Inf Dis.
2000;
(suppl) 181
426-429
-
71
Messmer T O, Martinez J, Hassouna F. et al .
Comparison of two commercial microimmunofluorescence kits for detection of serum immunoglobulin G antibodies to Chlamydia pneumoniae.
Clin Diagn Lab Immunol.
2001;
8
588-592
-
72
Hermann C, Graf K, Groh A. et al .
Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals.
J Clin Microbiol.
2002;
40
1603-1609
-
73
Tugwell P, Dennis D T, Weinstein A. et al .
Laboratory evaluation in the diagnosis of Lyme disease.
Ann Intern Med.
1997;
127
1109-1123
-
74
Bas S, Muzzin P, Ninet B. et al .
Chlamydial serology: comparative diagnostic value of immunoblotting, microimmunofluorescence test, and immunoassays using different recombinant proteins as antigens.
J Clin Microbiol.
2001;
39
1368-1377
-
75
Boman J, Allard A, Persson K. et al .
Rapid diagnosis of respiratory Chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA.
J Infect Dis.
1997;
175
1523-1526
-
76
Tong C, Sillis M.
Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR.
J Clin Pathol.
1993;
46
313-317
-
77
Campbell L A, Melgosa M P, Hamilton D J. et al .
Detection of Chlamydia pneumoniae by polymerase chain reaction.
J Clin Microbiol.
1992;
30
434-439
-
78
Gaydos C A, Roblin P M, Hammerschlag M R. et al .
Diagnostic utility of PCR-enzyme immunoassay, culture and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients.
J Clin Microbiol.
1994;
32
903-905
-
79
Hyman C L, Roblin P M, Gaydos C A. et al .
Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture.
Clin Infect Dis.
1995;
20
1174-1178
-
80
Mygind T, Birkelund S, Birkebaek N. et al .
Determination of PCR efficiency in chelex-100 purified clinic samples and comparison of real-time quantitative PCR and conventional PCR for detection of Chlamydia pneumoniae.
BMC Microbiol.
2002;
9
17
-
81
Tondella M L, Talkington D F, Holloway B P. et al .
Development and evaluation of real-time PCR-based fluorescence assays for detection of Chlamydia pneumoniae.
J Clin Microbiol.
2002;
40
575-583
-
82
Kuoppa Y, Boman J, Scott L. et al .
Quantitative detection of respiratory Chlamydia pneumoniae infection by real-time PCR.
J Clin Microbiol.
2002;
40
2273-2274
-
83
Apfalter P, Barousch W, Nehr M. et al .
Comparison of a new quantitative ompA-based real-time PCR TaqMan assay for detection of Chlamydia pneumoniae DNA in respiratory specimens with four conventional PCR assays.
J Clin Microbiol.
2003;
41
592-600
-
84
Reischl U, Lehne N, Simnacher U. et al .
Rapid and standized detection of Chlamydia pneumoniae using LightCycler real-time fluorescence PCR.
Eur J Clin Microbiol Infect Dis.
2003;
22
54-57
-
85
Welti M, Jaton K, Altwegg M. et al .
Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions.
Diagn Microbiol Infect Dis.
2003;
45
85-95
-
86
Poppert S, Essig A, Marre R. et al .
Detection and differentiation of Chlamydiae by fluorescence in situ hybridization.
Appl Environ Microbiol.
2002;
68
4081-4089
-
87
Niedermann M S, Mandell L A, Anzueto A. et al .
Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, initial antimicrobial therapy, and prevention.
Am J Respir Crit Care Med.
2001;
148
1730-1754
-
88
Schaberg T, Dalhoff K, Ewig S. et al .
Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Therapie der ambulant erworbenen Pneumonie.
Pneumologie.
1998;
51
450-462
-
89
Bartlett J G, Dowell F S, Mandell L A. et al .
Practice guidelines for the management of community acquired pneumonia in adults.
Clin Inf Dis.
2000;
31
347-382
-
90
Mandall L A, Marrie T J, Grossman R F. et al .
Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society.
Clin Infect Dis.
2000;
31
383-421
-
91
Hammerschlag M R.
Antimicrobial susceptibility and therapy of infections caused Chlamydia pneumoniae.
Antimicrob Agents Chemother.
1994;
38
1873-1878
-
92
Roblin P M, Kutlin A, Hammerschlag M R.
In vitro activity of trovafloxacin against Chlamydia pneumoniae.
Antimicrob Agents Chemother.
1997;
41
2033-2034
-
93
Roblin P M, Hammerschlag M R.
In vitro activity of a new 8-methoxyquinolone, BAY 12 - 8039, against Chlamydia pneumoniae.
Antimicrob Agents Chemother.
1998;
42
951-952
-
94
Hammerschlag M R, Qumei K K, Roblin P M.
In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae.
Antimicrob Agents Chemother.
1992;
36
1573-1574
-
95
Ridgway G L, Salman H, Robbins M J. et al .
In-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
J Antimicrob Chemother.
1997;
(suppl) 40
31-34
-
96
Miyashita N, Niki Y, Kishimoto T. et al .
In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
Antimicrob Agents Chemother.
1997;
41
1331-1334
-
97
Donati M, Rodriguez Fermepin M, Olmo A. et al .
Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.
J Antimicrob Chemother.
1999;
43
825-827
-
98
Kimura M, Kishimoto T, Niki Y. et al .
In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.
Antimicrob Agents Chemother.
1993;
37
801-803
-
99
Roblin P M, Kutlin A, Reznik T. et al .
Activity of grepafloxacin and other fluoroquinolones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae.
Int J Antimicrob Agents.
1999;
12
181-184
-
100
Roblin P M, Hammerschlag M R.
In vitro activity of Gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.
J Antimicrob Chemother.
1999;
44
549-551
-
101
Roblin P M, Reznik T, Kutlin A. et al .
In vitro activities of gemifloxacin (SB-265 805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
Antimicrob Agents Chemother.
1999;
43
2806-2807
-
102
Block S, Hedrick J, Hammerschlag M R. et al .
Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia; comparative efficacy and safety of clarithromycin vs erythromycin ethylsuccinate.
Pediatr Infect Dis J.
1995;
14
471-477
-
103
Roblin P M, Hammerschlag M R.
Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired peumonia.
Antimicrob Agents Chemother.
1998;
42
194-196
-
104
Balfour J A, Figgitt D P.
Telithromycin.
Drugs.
2001;
61
815-829
-
105
Roblin P M, Hammerschlag M R.
In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.
Antimicrob Agents Chemother.
1998;
42
1515-1516
-
106
Strigl S, Robin P M, Reznik T. et al .
In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.
Antimicrob Agents Chemother.
2000;
44
1112-1113
-
107
Dessus-Babus S, Bebear C M, Charron A. et al .
Sequencing of gyrase and topoisomerase IV quinolone-resistence-determining regions of Chlamydia trachomatis and characterization of quinolon-resistent mutants obtained in vitro.
Antimicrob Agents Chemother.
1998;
42
1474-2481
-
108
Hammerschlag M R.
Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review.
J Antimicrob Chemother.
2000;
(suppl) 45
35-39
-
109
Hammerschlag M R, Hyman C L, Roblin P M.
In vitro activities of five quinolones against Chlamydia pneumoniae.
Antimicrob Agents Chemother.
1992;
36
682-683
-
110
Woodcock J M, Andrews J M, Boswell F J. et al .
In vitro activity of BAY 12 - 8039, a new fluoroquinolone.
Antimicrob Agents Chemother.
1997;
41
101-106
-
111
Wise R, Andrews J M, Brenwald N.
The in-vitro activity of OPC-17 116, a new 5-methyl substituted quinolone.
J Antimicrob Chemother.
1993;
31
497-504
-
112
Roblin P M, Montalban G, Hammerschlag M R.
In vitro activities of OPC-17 116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
Antimicrob Agents Chemother.
1994;
38
1402-1403
-
113
Plouffe J F, Herbert M T, File jr T M. et al .
Ofloxacin versus standard therapy in treatment of community-acqired pneumonia requiring hospitalization. Pneumonia Study Group.
Antimicrob Agents Chemother.
1996;
40
1175-1179
-
114
File jr T M, Segreti J, Dunbar L. et al .
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
Antimicrob Agents Chemother.
1997;
41
1965-1972
Priv.-Doz. Dr. med. T. Welte
Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät · Abteilung für Pneumologie und Internistische Intensivtherapie
Leipziger Straße 44
39120 Magdeburg
eMail: tobias.welte@medizin.uni-magdeburg.de
